Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 17/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4721810 | 0.97 | SLC6A9 (0.57) | SLC6A9CYP2C9P2RX7 | |
| SCHEMBL3541643 | 0.81 | SLC6A9 (0.54) | SLC6A9CYP2C9 | |
| SCHEMBL678188 | 0.81 | SLC6A9 (0.54) | SLC6A9CYP2C9 | |
| SCHEMBL3541641 | 0.81 | SLC6A9 (0.54) | SLC6A9CYP2C9 | |
| SCHEMBL3545064 | 0.80 | SLC6A9 (0.60) | SLC6A9CYP2C9 | |
| SCHEMBL4719818 | 0.79 | SLC6A9 (0.58) | SLC6A9CYP2C9 | |
| SCHEMBL3547630 | 0.79 | SLC6A9 (0.50) | SLC6A9CYP2C9 | |
| SCHEMBL3547634 | 0.79 | SLC6A9 (0.50) | SLC6A9CYP2C9 | |
| SCHEMBL3541805 | 0.79 | SLC6A9 (0.50) | SLC6A9CYP2C9 | |
| SCHEMBL3541806 | 0.79 | SLC6A9 (0.50) | SLC6A9CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7626056-B2 | 2,4-Dichloro-N-(4-cyclopropylmethanesulfonyl-1-cyclopropylmethylcyclohexyl-methyl) benzamide; glutamatergic neurotransmission dysfunction and diseases; dementia; antidepressants; learning enhancement; cognition activators; attention deficit disorders; autism; eating disorders; anxiolytic agents | MERCK SHARP & DOHME LIMITED (GB) | 2009-12-01 | — | — | US | disclosed |
| US-20060276655-A1 | Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276655-A1 | Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia | GLRA1, GNMT, MGAT1 | SLC6A9 71/4885CYP2C9 1409/4885P2RX7 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.